New president and CEO for AEON Biopharma

 

ALPHAEON Corp. has named Marc Forth as president and CEO of the company’s newly established, wholly owned subsidiary. AEON Biopharma Inc. was established to independently pursue the rapidly growing, multi-billion-dollar, therapeutic toxin market. Therapeutic related applications represent greater than 60 percent of global neurotoxin segment revenues. Forth joins AEON Biopharma from Allergan, where he was senior VP of Neurosciences, Urology, and Medical Dermatology. Forth led, among other brands, Botox Therapeutic, an organization with annual revenues of about $2 billion.

Forth has more than 25 years of commercial and executive experience building and launching multiple market leading franchises. He previously also led marketing for Botox Cosmetic and held various sales and marketing roles of increasing responsibility at TAP Pharmaceuticals.

“Marc’s joining AEON Biopharma represents a major milestone for the company, as we move towards filing an investigative new drug application for the first therapeutic indication of our 900 kDa purified botulinum toxin type A complex,” says Simone Blank, chairperson of ALPHAEON. “Marc is one of the most experienced executives in the field of therapeutic neurotoxins, having led Botox Therapeutic, the largest therapeutic neurotoxin in the world. We believe his joining further validates the promise of our botulinum toxin type A complex. We welcome Marc’s vision and passion.”

Forth says, “I am excited to join the company at a time when the therapeutic toxin market is already large and rapidly growing, yet also presents an expansion opportunity into several untapped new indications. I believe AEON Biopharma, with its focus on therapeutic indications only, is optimally positioned to become one of the leading players in the world of therapeutic neurotoxins. I look forward to working with the company’s Board in assembling a best-in-class leadership team to help further this incredible business opportunity.”